Idorsia Ltd (SWX: IDIA)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 338.55M |
| Revenue | 127.84M |
| Net Income | 28.66M |
| Shares Out | 180.08M |
| EPS | 0.16 |
| PE Ratio | 11.74 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 589,987 |
| Open | 1.880 |
| Previous Close | 1.880 |
| Day's Range | 1.794 - 1.897 |
| 52-Week Range | 1.294 - 5.020 |
| Beta | 1.18 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 29, 2024 |
About Idorsia
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemor... [Read more]
News
Amended terms of Idorsia's 2024 convertible bonds become effective
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – September 2, 2024 Idorsia Ltd (SIX: IDIA) today announced that following the expiry of the appeal period – during which no appeal wa...
Invitation to Idorsia's Half Year 2024 Financial Reporting webcast and conference call
Idorsia will publish its Half Year 2024 Financial Reporting on Thursday July 25, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.
Idorsia's JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
Allschwil, Switzerland – July 1, 2024 Idorsia Ltd (SIX: IDIA) announced today that the European Commission (EC) has approved JERAYGO™ (aprocitentan) for the treatment of resistant hypertension in adul...
Idorsia's novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality' category
Allschwil, Switzerland – June 21, 2024 Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the prestigious Prix Galien Suisse 2024 innovation prize i...
Idorsia holds its Annual General Meeting of Shareholders
Allschwil, Switzerland – June 13, 2024 At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Direc...
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
Allschwil, Switzerland – May 23, 2024 Idorsia Ltd (SIX: IDIA) today issued the invitation to the upcoming Annual General Meeting (AGM) of Shareholders on behalf of the Board of Directors. The meeting ...
Idorsia announces changes to Idorsia Executive Committee and Board of Directors
Ad hoc announcement pursuant to Art. 53 LR Jean-Paul Clozel to retire as CEO and stand for election as Chairman of the Board of Directors Mathieu Simon to stand for re-election to the Board – taking o...
Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – May 21, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the full year of 2023.
Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
Idorsia will publish its Full Year 2023 and Q1 2024 Financial Reporting on Tuesday May 21, 2024, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same ...
Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
Ad hoc announcement pursuant to Art. 53 LR The proposed consent fee will be increased to 8'000'000 Idorsia shares.
Idorsia publishes an invitation to a bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR A bondholder meeting will take place on May 6, 2024, to vote on proposals to amend the terms of the outstanding convertible bonds maturing on July 17, 2024, ...
Idorsia publishes a Financial Status required for an upcoming bondholder meeting
Ad hoc announcement pursuant to Art. 53 LR Unaudited Financial Status as of March 31, 2024, required for an upcoming bondholder meeting, now available on the company website Bondholder meeting now pla...
Idorsia takes steps to address short-term liquidity needs
Ad hoc announcement pursuant to Art. 53 LR A bondholders meeting is expected to take place on April 30, 2024, to request the right to repay the bonds maturing in 2024, fully or partially in shares of ...
Idorsia thanks Guy Braunstein for his years of service as he retires
Allschwil, Switzerland – March 22, 2024 Idorsia Ltd (SIX: IDIA) today announced that Guy Braunstein, who has served as Chief Medical Officer (CMO) since 2022 and Head of Global Clinical Development an...
US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) - the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult pati...
US FDA approves Idorsia's once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensives
Ad hoc announcement pursuant to Art. 53 LR TRYVIO™ (aprocitentan) is indicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult pati...
Idorsia presents at the J.P. Morgan Healthcare Conference – Adapting Idorsia for sustainable value creation
Ad hoc announcement pursuant to Art. 53 LR CEO, Jean-Paul Clozel, to update on how Idorsia is being adapted for sustainable value creation The company is focused on extending the cash runway beyond th...
Idorsia announces financial results for the first nine months of 2023 – adapting the company to create sustainable value
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 24, 2023 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2023.
Idorsia is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023
Allschwil, Switzerland – October 23, 2023 Idorsia Ltd (SIX: IDIA) today announced that it is committed to further the science of sleep with a symposium and poster presentations at World Sleep 2023, a ...
Invitation to Idorsia's Nine-Month 2023 Financial Reporting webcast and conference call
Idorsia will publish its Nine-Month Financial Reporting 2023 on Tuesday October 24, 2023, at 07:00 CEST. An investor conference call and webcast will be held to discuss the results on the same day.
Idorsia reacquires the world-wide rights to aprocitentan
Ad hoc announcement pursuant to Art. 53 LR Aprocitentan, Idorsia's oral, dual endothelin receptor antagonist is currently under review with health authorities for the treatment of patients with resist...
Idorsia announces financial results for the first half 2023 – adapting the company to create sustainable value
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – July 25 , 202 3 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first half of 2023.
Idorsia announces a cost reduction initiative to be implemented by the end of 2023
Ad hoc announcement pursuant to Art. 53 LR In order to give Idorsia the necessary time to realize commercial success – any funds that are raised must be prioritized on activities to maximize their ret...
Sosei Heptares - Investor and Press Conference on Today's Announcement Regarding the Acquisition and License Transaction with Idorsia
Tokyo, Japan and Cambridge , UK, 20 July 2023 – Sosei Group Corporation (“the Company”; TSE: 4565), will hold an investor and press conference on today's announcement; “Sosei Heptares Acquires Idorsia...
Sosei Heptares Acquires Idorsia's Pharmaceuticals Business in Japan and APAC (ex-China), Accelerating its Transformation into a Fully Integrated Biopharmaceutical Company
Tokyo, Japan and Cambridge, UK, 20 July 202 3 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that it has resolved, at a meeting of the Board of Directors held on 20 July 2023, to acqui...